Xilio Therapeutics to Present at Upcoming Investor Conferences
02/27/2023 - 07:30 AM
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences:
Cowen 43rd Annual Healthcare Conference on Monday, March 6, 2023, at 9:10 a.m. ET as part of a discussion called Novel Immuno-Oncology (IO) Corporate Panel. Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, with a virtual presentation at 4:00 p.m. ET. A live webcast of the presentations can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/ . A replay of the webcasts will be archived on the website for 30 days following each presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on Twitter (@xiliotx ) and LinkedIn (Xilio Therapeutics, Inc. ). This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.For Investor Inquiries: Melissa Forst Argot Partnersxilio@argotpartners.com
For Media Inquiries: Julissa Viana Vice President, Corporate Communicationsmedia@xiliotx.com
Xilio Therapeutics Inc
NASDAQ:XLO
XLO Rankings
#2791 Ranked by Stock Gains
XLO Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About XLO
xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.